Insmed Stock Forecast
NASDAQ: INSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 2:17 PM ET
INSM analyst consensus
Consensus (24 analysts)
strong_buy
Avg. price target
$197.74+96.44%
- Strong buy 5
- Buy 19
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 24 Wall Street analysts covering Insmed (2026-10-07), 24 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $197.74, with a high estimate of $243.00 and a low estimate of $169.00. The average target implies upside of 96.4% from the current price of $100.66.
The spread between the highest and lowest targets is 43.8%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for INSM.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 5 | 21% |
| Buy | 19 | 79% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $169.00 | +67.89% |
| Average target | $197.74 | +96.44% |
| High target | $243.00 | +141.41% |